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1. Introduction 
Considerable evidence now exists that myasthenia 
gravis is an autoimmune disease where acetylcholine 
receptor (AChR) is a major autoantigen. Cellular and 
humoral sensitivity to AChR are observed in patients 
with myasthenia gravis [l-4] . Experimental uto- 
immune myasthenia gravis (EAMG) induced in several 
animal species by the injection of purified AChR 
[5-l 0] has been demonstrated tobe an appropriate 
model for the human disease. It is still not known 
which part(s) or antigenic determinant(s) in the AChR 
molecule are responsible for its myasthenic activity 
and whether these are overlapping with any site(s) 
involved in its physiological function. Detailed 
immunochemical nalysis of AChR should throw 
light on these questions. 
AChR is a multisubunit protein molecule [1 l-141 
which seems to dissociate only under denaturing 
conditions. In this report we describe the preparation 
of an irreversibly denatured erivative of AChR 
obtained by complete reduction and carboxymethyla- 
tion in 6 M guanidine hydrochloride and the immuno- 
chemical analysis of this preparation. 
2. Materials and methods 
AChR was isolated from the electric organ of 
7ii~edo carifornica (Pacific Bio-Marine, Venice, Ca.) 
and was purified as described elsewhere [ 141. 
Iodinations with “‘1 of ar-bungarotoxin (cr-Bgt), 
AChR and reduced-carboxymethylated AChR 
(RCM-AChR) were performed by the chloramine-T 
method [ 151. Specific binding of cu-Bgt to AChR and 
214 
RCM-AChR was assayed by measuring the amount 
of ‘251-labeled Bgt which coprecipitates with the 
receptor in 35% saturated ammonium sulfate [ 14,161. 
2.1. Preparation of reduced-carboxymethylated 
AG’zR (RCiWAChR) 
AChR (0.8 mg/ml) was dialyzed for 3 h against 
6 M guanidine-HCl in 0.2 M Tris-buffer, pH 8.5. 
Reduction was performed with 0.1 M fl-mercapto- 
ethanol for 60 min at 37°C under nitrogen. The 
sulfhydryl groups were blocked by the addition of 
crystalline iodoacetamide toa final concentration of 
0.15 M and maintaining pH 8.2 for 15 min by titration 
with 2 M Tris-base. RCM-AChR was dialysed against 
0.01 M Tris-buffer, pH 7.5, containing 0.1 M NaCl, 
IO-’ M EDTA, low5 M PMSF, 5 X 1 O4 NaN3 and 
0.01% Triton X-100. 
2.2. Immunization 
Rabbits were immunized twice (or three times) 
each time with 100 pg RCM-AChR (in 1 ml) emulsified 
with equal vol. complete Freund’s adjuvant. Injections 
were given intradermally at multiple sites at 30 day 
intervals. For comparison other rabbits were injected 
once with AChR and if they did not die of EAMG 
they were given a similar booster injection of AChR 
after 30 days. 
2.3. Immunological ssays 
Sera from the immunized rabbits were analyzed by 
quantitative precipitin reactions, immunodiffusion, 
micropassive h magglutination a d radioimmunoassay. 
For the radioimmunoassay serum dilutions (0.1 ml 
in 10% normal rabbit serum) were incubated with the 
radioactive antigen (‘251-labeled AChR or 125 I-labelled 
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RCM-AChR) for 30 min at 37°C. Goat anti-rabbit 
immunoglobulin serum (0.1-0.2 ml) was added and 
the tubes were incubated for 30 min at 37’C and 
then overnight at 4°C. The centrifuged precipitates 
were washed twice and counted in an autogamma 
scintillation counter. For inhibition experiments, 
preincubation of the antiserum (at a dilution that 
binds -40% of the radioactive antigen) with different 
amounts of the inhibitor was performed for 30 min 
at 37°C and the assay was continued as described 
above for the binding. 
2.3. Effect of antibodies on 1251-labeled ol-Bgt-binding 
to AChR 
The inhibition by antisera of the binding of toxin 
to AChR was measured by preincubation of AChR 
with increasing amounts of serum for 30 min at 37°C 
before the addition of 1251-labeled cr-Bgt and determina. 
tion of the degree of toxinbinding relative to the 
binding obtained in the absence of serum. 
3. Results 
3.1. Characterization of reduced-carboxymethylated 
AChR (RCM-ACTIR) 
Denaturation of AChR was performed by reduction 
0.5 1 I I I I 
(A) anti - AChR 
and carboxymethylation i  6 M guanidine-HCl. 
Amino acid analysis of RCM-AChR demonstrated no 
significant change in amino acid composition apart 
from the conversion of all cystines and cysteine 
residues to S-carboxymethyl cysteine. Analytical 
velocity ultracentrifugation f RCM-AChR revealed 
one major component of 9.6 S suggesting that the 
constituent subunits were held together even after 
reduction and carboxymethylation. Electrophoresis 
of RCM-AChR on SDS-acrylamide gels [ 171 gave a 
similar pattern to that obtained with the unmodified 
receptor, with a slight difference in the relative colour 
intensity of the various bands. 
RCM-AChR did not show any detectable binding 
of r2’I-labeled o-Bgt. 
3.2. Immunological characterization of RCM-AChR 
Rabbits immunized with RCM-AChR developed 
antibodies reacting both with the immunizing RCM- 
AChR and with AChR. Figure 1 shows the cross- 
reactivity between RCM-AChR and AChR as measured 
by the quantitative precipitin reaction. Rabbits 
immunized repeatedly with RCM-AChR do not 
develop any clinical signs of EAMG although they 
have high titers of antibodies reacting with AChR. 
‘Ihis is in contrast o the onset of the disease in 
I I I I 
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Fig.1. Precipitin reaction of anti-AChR serum (A) and anti-RCM-AChR serum (B) with AChR (0) and RCM.AChR (0). 
I I I I 
(8) anti - RCM-AChR 
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rabbits usually following one injection (or occasionally 
two) with AChR. 
In addition to the cross-precipitation the cross- 
reactivity between RCM-AChR and AChR was 
demonstrated also by micropassive hemagglutination 
and radioimmunoassay. Anti-AChR and anti-RCM- 
AChR sera agglutinate AChR-coated formalinized 
sheep erythrocytes [ 181 and give similar hemagglutina- 
tion titers. Both antisera bind 1251-labeled AChR and 
1251-labeled RCM-AChR to a similar extent. 
The antigenic specificity of the immune response 
elicited by RCM-AChR is different from that elicited 
by AChR. Immunodiffusion experiments (fig.2) 
demonstrate identity between the reaction of anti- 
RCM-AChR serum with RCM-AChR and AChR 
indicating that all the antibodies that are precipitable 
by the homologous RCM-AChR can be precipitated 
also by AChR. On the other hand, anti-AChR serum 
shows only a partial cross-reactivity with RCM-AChR 
(fig.2), suggesting the presence in this antiserum of 
antibodies against some antigenic determinants which 
do not exist on the denatured receptor. 
The antigenic specificity of RCM-AChR and AChR 
was determined also by quantitative inhibition of the 
binding of radioactively labeled AChR and RCM- 
Fig.2. Immunodiffusion of anti-RCM-AChR Serum (well 1) 
and anti-AChR serum (well 4) with RCM-AChR (wells 2, 3,s) 
and AChR (wells 6, 7). 
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Fig.3. Inhibition of the binding of ‘ZSI-labeled AChR (0) and 
‘zsI-labeled RCM-AChR (0) to anti-AChR serum (left) and 
anti-RCM-AChR serum (right) by AChR (- ) and RCM- 
AChR (- - - -). 
AChR to the different antisera by the non-labeled 
antigens. Whereas RCM-AChR and AChR inhibit to 
the same xtent the binding of ‘251-labeled AChR to 
sera of rabbits immunized with RCM-AChR (fig.3, 
top, right) RCM-AChR is a much weaker inhibitor 
than the unmodified AChR, of the binding of 12’1- 
labeled AChR to antisera of rabbits injected with 
AChR (fig.3, top, left). There is no significant 
difference in the extent of inhibition by RCM-AChR 
and AChR of the binding of ‘251-labeled RCM-AChR 
to anti-RCM-AChR or anti-AChR sera (fig.3, bottom). 
3.3. Effect of antibodies on the binding of bungaro- 
toxin to AChR 
Antibodies to AChR were shown to block AChR 
physiological ctivity [ 19-211 and to inhibit the 
binding of bungarotoxin to the receptor [ 141. 
Comparison of the effect of antibodies against AChR 
with that of antibodies against RCM-AChR (fig.4) on 
the binding of ‘251-labeled a-Bgt to AChR shows that 
the latter antibodies block this binding only to a very 
limited extent. This differential blockifig activity by 
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Serum added (dilution) 
Fig.4. Inhibition of “Tlabeled cr-Bgt binding to AChR by 
anti-AChR serum ( -), anti-RCM-AChR serum (- - - -) and 
normal rabbit serum (-.-.-). 
the two antisera is compatible with the different 
antigenic specificities of the two immunogens, resulting 
from the abolishment of some antigenic determinant(s) 
of the receptor molecule by the denaturation 
procedure. 
4. Discussion 
The molecular structure of AChR is complex. It is 
therefore desirable to analyse it both biochemically 
and immunologically on a lower level of complexity. 
In attempts to correlate specific structural features 
of AChR with its unique autoantigenic activity, the 
immunological properties of the pharmacologically 
inactive RCM-AChR was studied. RCM-AChR is a 
good immunogen and elicits upon injection into 
rabbits high titers of antibodies which cross-react 
with the intact receptor. However, repeated immuniza- 
tions with RCM-AChR does not induce any symptoms 
of EAMG. Similar results were reported by Valderrama 
et al. [22] and by Lindstrom et al. [23] with SDS- 
denatured AChR. 
The titers of antibodies reacting with AChR in 
sera of rabbits immunized with RCM-AChR with no 
signs of EAMG, are at least as high as the antibody 
titers in myasthenic rabbits injected with intact 
AChR. Thus a high anti-AChR antibody titer is not 
by itself a sufficient condition for production of 
EAMG. In fact, since RCM-AChR does not induce 
EAMG several booster injections can be given, 
resulting in an increase of the antibody titers against 
both RCM-AChR and AChR. 
It seems that the major difference between AChR 
and RCM-AChR leading to their different pathogenic@ 
resides in their different antigenic specificity. The 
analysis of the antigenic specificities of both systems 
suggests that some antigenic determinants in the 
AChR molecule were abolished by the denaturation 
procedure. However, no additional determinants which 
were not expressed in the intact molecule became 
immunopotent after reduction and carboxymethyla- 
tion. 
The different antigenic specificity of antibodies to 
AChR and RCM-AChR along with their different 
effect in blocking toxin binding to AChR leads us to 
propose that the denaturation of AChR destroyed 
some antigenic determinant(s) which is (are) important 
for the induction of EAMG, and which may be located 
closely to the toxin-binding site. We have preliminary 
results which demonstrate that although RCM-AChR 
does not induce EAMG, it can be effective in 
immunosuppression of the disease either by preventing 
its onset or even by curing it. The cross-reactivity 
between RCM-AChR and AChR and the non-patho- 
genicity of RCM-AChR appear to be crucial in 
governing the immunosuppressive ffect of RCM- 
AChR on EAMG. 
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